12:00 AM
 | 
Jul 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

APPY1: Pivotal trial ongoing

Venaxis said an independent DSMB recommended continuation of a U.S. pivotal trial to evaluate APPY1 based on the first of 2 futility analyses. The analysis included data from the first 579 patients. The second analysis will include data from the first 1,200 patients. The trial is...

Read the full 207 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >